| Literature DB >> 27741272 |
Katharina Bell1, Jochen Fleckenstein1, Frank Nuesken1, Norbert Licht1, Christian Rübe1, Yvonne Dzierma1.
Abstract
BACKGROUND: The recently implemented mARC-rotation-technique is capable to deliver high dose rate bursts. For the case of hypopharynx cancer plans we evaluate whether the mARC can achieve an advantage in treatment time in comparison to IMRT. These plans consider two arcs with flat and flattening filter free (FFF) beam energies.Entities:
Mesh:
Year: 2016 PMID: 27741272 PMCID: PMC5065169 DOI: 10.1371/journal.pone.0164616
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Schematic illustration of mARC delivery.
DVH criteria for plan acceptability.
| PTV | V(95%) > 95% |
| V(105%) < 5% | |
| Spinal cord | Dmax < 27 Gy |
| Extended spinal cord (+ 5 mm) | Dmax < 33 Gy |
| Parotid glands | V(14Gy) < 30% |
Fig 2Example dose distributions for the four plan scenarios (transverse slice).
Fig 3Example DVH (same patient as in Fig 2).
Measures of quality for the four plan scenarios (mean values ± standard deviation and range).
| Index | 6 MV IMRT | 7 MV FFF IMRT | 6 MV mARC | 7 MV FFF mARC |
|---|---|---|---|---|
| PTV D50% (Gy) | 50.44±0.25 (49.9–50.7) | 50.65±0.2 (50.3–50.9) | 50.83±0.51 (50.0–51.5) | 50.49±0.46 (49.8–51.1) |
| CI | 0.78±0.04 (0.69–0.81) | 0.78±0.02 (0.75–0.8) | 0.85±0.02 (0.83–0.88) | 0.86±0.02 (0.82–0.88) |
| HI | 0.16±0.019 (0.14–0.18) | 0.17±0.013 (0.14–0.18) | 0.17±0.02 (0.14–0.2) | 0.16±0.03 (0.11–0.19) |
| Spinal cord D1% (Gy) | 24.99±1.84 (22.2–26.7) | 24.88±1.75 (22.1–26.3) | 26.25±0.53 (25.4–27.0) | 25.66±0.46 (24.8–26.1) |
| Spinal cord D2% (Gy) | 24.67±1.91 (21.84–26.5) | 24.6±1.84 (21.7–26.1) | 26.04±0.44 (25.3–26.6) | 25.47±0.49 (24.6–26) |
| Parotid mean (Gy) | 12.96±1.98 (7.85–15.25) | 12.36±2.12 (6.95–14.8) | 12.23±2.52 (6.1–14.45) | 11.36±2.01 (6.15–13.1) |
| Parotid V20% (Gy) | 18.60±3.92 (10.6–24.4) | 18.07±3.33 (10.5–23.54) | 17.80±3.57 (8.12–21.24) | 16.65±2.88 (9.3–20.03) |
CI: Conformity Index, HI: Homogeneity Index.
Results of the two-way anova with repeated measures and interactions (p-values of pairwise tests for the measures of quality).
| Index | Energy | Technique | Interaction | p(6 MV IMRT—mARC) | p(7 MV FFF IMRT—mARC) | p(IMRT 6 MV– 7 MV FFF) | p(mARC 6 MV– 7 MV FFF) |
|---|---|---|---|---|---|---|---|
| PTV D50% (Gy) | n.s. | n.s. | 0.0074 | 0.019 | n.s. | n.s. | 0.034 |
| CI | n.s. | 1.6e-4 | n.s. | 4.9e-4 | 4.5e-4 | n.s. | n.s. |
| HI | n.s. | n.s. | 0.026 | 0.046 | n.s. | n.s. | 0.032 |
| Spinal cord D1% (Gy) | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. |
| Spinal cord D2% (Gy) | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. |
| Parotid mean (Gy) | 4.8e-5 | 0.0062 | n.s. | 0.015 | 0.0025 | 0.037 | 0.0058 |
| Parotid V20% (Gy) | 0.00973 | n.s. | n.s. | n.s. | 0.027 | n.s. | n.s. |
n.s.: not significant, CI: Conformity Index, HI: Homogeneity Index.
Monitor units, treatment times and scattered dose for the four plan scenarios (mean values ± standard deviation and range).
| Index | 6 MV IMRT | 7 MV FFF IMRT | 6 MV mARC | 7 MV FFF mARC |
|---|---|---|---|---|
| Monitor units | 598±89 (485–729) | 779±95 (628–918) | 406±32 (363–459) | 758±92 (644–897) |
| Treatment times (min:sec) | 9:09±0:32 (8:33–10:09) | 7:46±0:14 (7:22–8:08) | 6:19±0:06 (6:09–6:29) | 5:30±0:04 (5:25–5:37) |
| Dose at breast (mGy) | 24.1±2.63 (20.4–27.7) | 20.5±3.12 (16.8–25.7) | 17.9±4.13 (13.4–22.6) | 15.4±2.87 (12.3–18.4) |
Results of the two-way anova with repeated measures and interactions (p-values of pairwise tests for monitor units, treatment times and scattered dose).
| Index | Energy | Technique | Interaction | p(6 MV IMRT—mARC) | p(7 MV FFF IMRT—mARC) | p(IMRT 6 MV– 7 MV FFF) | p(mARC 6 MV– 7 MV FFF) |
|---|---|---|---|---|---|---|---|
| Monitor units | 1.79e-6 | 0.00223 | 0.0124 | 5.1e-4 | n.s. | 7.6e-4 | 1.09e-5 |
| Treatment times (min:sec) | 1.36e-5 | 5.75e-8 | 0.0447 | 3.2e-7 | 1.4e-6 | 4.3e-5 | 0.00108 |
| Dose at breast (mGy) | 1.73e-5 | 7.78e-6 | n.s. | 1.2e-5 | 4.3e-5 | 3.98e-4 | 0.00303 |
n.s.: not significant